BIOMARKER:

GNAQ mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

GNAQ mutation	Melanoma	GNAQ mutation	Melanoma	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2
GNAQ mutation	Melanoma	GNAQ mutation	Melanoma	vorinostat Sensitive: C2 – Inclusion Criteria vorinostat Sensitive : C2	vorinostat Sensitive: C2 – Inclusion Criteria vorinostat Sensitive : C2
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	cabozantinib capsule Sensitive: C3 – Early Trials cabozantinib capsule Sensitive : C3	cabozantinib capsule Sensitive: C3 – Early Trials cabozantinib capsule Sensitive : C3
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	AEB071 Sensitive: C3 – Early Trials AEB071 Sensitive : C3	AEB071 Sensitive: C3 – Early Trials AEB071 Sensitive : C3
GNAQ mutation	Renal Cell Carcinoma	GNAQ mutation	Renal Cell Carcinoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
GNAQ mutation	Melanoma	GNAQ mutation	Melanoma	trametinib + dabrafenib Sensitive: C3 – Early Trials trametinib + dabrafenib Sensitive : C3	trametinib + dabrafenib Sensitive: C3 – Early Trials trametinib + dabrafenib Sensitive : C3
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	AEB071 + AHT956 Sensitive: D – Preclinical AEB071 + AHT956 Sensitive : D	AEB071 + AHT956 Sensitive: D – Preclinical AEB071 + AHT956 Sensitive : D
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	Tris DBA Sensitive: D – Preclinical Tris DBA Sensitive : D	Tris DBA Sensitive: D – Preclinical Tris DBA Sensitive : D
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	FR900359 Sensitive: D – Preclinical FR900359 Sensitive : D	FR900359 Sensitive: D – Preclinical FR900359 Sensitive : D
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	AEB071 + CGM097 Sensitive: D – Preclinical AEB071 + CGM097 Sensitive : D	AEB071 + CGM097 Sensitive: D – Preclinical AEB071 + CGM097 Sensitive : D
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	everolimus + AEB071 Sensitive: D – Preclinical everolimus + AEB071 Sensitive : D	everolimus + AEB071 Sensitive: D – Preclinical everolimus + AEB071 Sensitive : D
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	binimetinib + AEB071 Sensitive: D – Preclinical binimetinib + AEB071 Sensitive : D	binimetinib + AEB071 Sensitive: D – Preclinical binimetinib + AEB071 Sensitive : D
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	PD-0325901 + AEB071 Sensitive: D – Preclinical PD-0325901 + AEB071 Sensitive : D	PD-0325901 + AEB071 Sensitive: D – Preclinical PD-0325901 + AEB071 Sensitive : D
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	binimetinib + STA-4783 Sensitive: D – Preclinical binimetinib + STA-4783 Sensitive : D	binimetinib + STA-4783 Sensitive: D – Preclinical binimetinib + STA-4783 Sensitive : D
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	STA-4783 Sensitive: D – Preclinical STA-4783 Sensitive : D	STA-4783 Sensitive: D – Preclinical STA-4783 Sensitive : D